Alterations of the salivary and fecal microbiome in patients with primary sclerosing cholangitis

Background Primary sclerosing cholangitis (PSC) is a chronic, progressive liver disease known for its frequent concurrence with inflammatory bowel disease. PSC can progress to cirrhosis, end-stage liver disease, hepatobiliary cancer, and/or colorectal cancer. The etiopathogenesis of PSC remains poorly understood, and, as such, pharmacotherapy has yet to be definitively established. Little is known about the salivary microbiome in PSC and PSC-IBD. This study aimed to evaluate the oral microbiome of patients with PSC, with association to these patient's fecal microbial composition. Methods Saliva, fecal samples and Food Frequency Questionnaires were collected from 35 PSC patients with or without concomitant inflammatory bowel disease and 30 age- and BMI-matched healthy volunteers. 16S rRNA gene sequencing was performed using Illumina MiSeq platform. Results The salivary microbial signature of PSC was significantly altered as compared to healthy controls, independent of concomitant IBD, and was comprised of 19 significantly altered species, of which, eight species were consistently overrepresented in both fecal and saliva of patients with PSC, includingVeillonella,ScardoviaandStreptococcus. Conclusions PSC is characterized by microbial dysbiosis in the gut and the salivary microbiome, independently from IBD. The PSC dysbiotic signature includes a reduction in autochthonous bacteria and an increased relative abundance of pathogenic bacteria, including an invasion of oral bacteria to the gut. PSC is a strong modulator of the microbial profile, in the gut and the oral microbiome. These results may lead to the development of biomarkers for screening and early diagnosis or the development of personalized medicine in PSC.

Automated summary

Primary sclerosing cholangitis (PSC) is a chronic liver disease often associated with inflammatory bowel disease. This study found that the salivary microbiome of PSC patients differs significantly from healthy controls, regardless of the presence of concurrent IBD. The dysbiotic signature in PSC includes both a reduction in beneficial bacteria and an increase in pathogenic bacteria, with oral bacteria potentially invading the gut. These findings may have implications for the development of biomarkers for early diagnosis or personalized medicine in PSC.